TCT-211: The SYNTAX Trial at 3 Years: A Global Risk Approach to Identify Patients With 3-Vessel &/or Left Main Stem Disease Who Could Safely & Efficaciously Be Treated With Percutaneous Coronary Intervention Part 2: The All-Comers SYNTAX Population
2011 ◽
Vol 58
(20)
◽
pp. B57
2011 ◽
Vol 58
(20)
◽
pp. B87
2019 ◽
2020 ◽
Vol 96
(4)
◽